Tables

 2024-05-29

Additional data files has been uploaded to the RAW data section of the repository. 

 

Patient and sample characteristics

More detailed clinical information is available in a separate document

Patient number M-protein SPEP fraction Days follow-up a Samples measured by MSb
1 IgA lambda beta 1422 33
2 IgG kappa gamma 584 12
3 IgG kappa gamma 760 31
4 IgA lambda gamma 1512 30
5 IgG kappa gamma 1707 36
6 IgA kappa gamma 702 26
7 IgG kappa gamma 918 17
8 IgG kappa gamma 1799 32
9 IgG kappa gamma 1914 28

 anumber of days between the first and the last time point in the disease, measured by mass spectrometry (MS)

beach sample represents serum of a distinct time point in the disease course, analyzed by serum protein electrophoresis (SPEP) and excised for MS measurement,

 

 

 

De novo sequence results for the selected multiple myeloma patients.

Patient number M-protein chain De novo M-protein peptide sequence ALC %  c Germline peptide sequence
1 heavy DSVFLQMNSLR b 73 NSLYLQMNSLR
2 heavy DGQLVESGGGSAQPGGSLR a 86 EDQLVESGGGLVQPGGSLR
3 heavy LSCEASGFTFR 91 LSCAASGFTF
4 heavy SPPVSVSHVEANSPGQTASLTCSGDK 72 SYELTQLPSVSVSPGQTARITCSGDV
5 heavy MTNMDPVDTATYYCARb 76 MTNMDPVDTATYYCAR d
5 light LVLTQSPATLSLSASPNAAK  a 73 IVLTQSPATLSLSP
6 heavy VELLVESGGDLVQPGGSLR 82 LVESGGGLVQPGGSLR
6 light LEVLTQSPGTLSLSPDAR 82 VLTQSPGTLSLSPGER
7 heavy EDTALFYCVK 84 EDTAVYYCVK
7 light DLQMTQSPSSLSASVGDK b 78 DIQMTQSPSSLSASVGDR
8 heavy SMTAADTGVYYCAR 80 SVTAVDTGVYYCAR
8 light QLDLTQSPSSLSASVGDR 72 IQLTQSPSSLSASVGDR
9 light LSLYGASNLQGGVPSK a 76 LLIYSASNLQSGVPSR

a de novo sequences derived from targeted measurements is shown, with differences to DDA based data

b The peptide was monitored with all methionine residues in the oxidized form

c ALC = average local confidence score from PEAKS

d The germline peptide lacks an N-terminal tryptic site.

 

 

Sequence, m/z, charge states and fragment types of selected patient-specific M-protein peptides used for M-protein monitoring with targeted mass spectrometry.

Patient Sequence m/z z Fragments
1 DSVFLQM[Ox]NSLR 663.3295 2 y5-8
2 DGQLVESGGGSAQPGGSLR 886.4321 2 y6; y11-15
3 LSC[CAM]EASGFTFR 637.7953 2 y5-10
4 SPPVSVSHVEANSPGQTASLTC[CAM]SGDK 871.4134 3 y6; y8-10; y13
5 M[Ox]TNM[Ox]DPVDTATYYC[CAM]AR 970.8948 2 y4; y6-9; y11
6 VELLVESGGDLVQPGGSLR 963.0206 2 y6-9; y11-14
7 EDTALFYC[CAM]VK 623.2946 2 y4-8
8 SM[Ox]TAADTGVYYC[CAM]AR 791.3372 2 y5; y7-12
9 LSLYGASNLQGGVPSK 795.9279 2 y3, y6, y10-13

[Ox] = oxidation

[CAM] = carbamidomethylation

 

 

DNA and de novo sequencing results of the reference patient.

Differences between the patient specific M-protein and the most homologous germline sequence are bold. Differences between the de novo sequencing result and the DNA-derived sequence are in red. No light chain DNA data was available to validate sequences obtained from de novo sequencing for the light chain. Trypsin cleavage sites are indicated with | symbols.